Carbidopa/entacapone/levodopa - LobSor Pharmaceuticals

Drug Profile

Carbidopa/entacapone/levodopa - LobSor Pharmaceuticals

Alternative Names: Entacapone/levodopa/carbidopa - LobSor Pharmaceuticals; LECIGel; LECIGon; Levodopa/carbidopa/entacapone - LobSor Pharmaceuticals; TRIGEL - LobSor Pharmaceuticals

Latest Information Update: 05 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LobSor Pharmaceuticals
  • Class Antiparkinsonians; Catecholamines; Catechols; Hydrazines; Nitriles; Small molecules
  • Mechanism of Action Catechol-O-methyltransferase inhibitors; Decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 02 Nov 2015 Pharmacokinetics data from a clinical study in Parkinson's disease released by LobSor Pharmaceuticals
  • 11 Jun 2015 LobSor Pharmaceuticals plans a MAA filing for regulatory approval in Parkinson's disease
  • 01 May 2015 Phase-I clinical trials in Parkinson's disease in Sweden (Intraduodenal) (NCT02448914)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top